Leukaemia & Lymphoma Research today welcomes a government report in which its innovative clinical trials programme has been recognised as a model of good practice.
In the report Strategy for UK Life Sciences One Year On, the government has acknowledged the value of the Trials Acceleration Programme (TAP) which Leukaemia & Lymphoma Research launched earlier this year.
The TAP programme enables patients to have greater access to new treatments and links 13 leading hospitals across the UK.
The programme is designed to shorten the time it takes to get new clinical trials up and running, as well as completed. Early results indicate a significant reduction not only in time scales but also in costs.
If successful, TAP will make the UK an attractive place for international pharmaceutical companies to undertake trials. This would increase patients’ access to new treatments, add financial benefit and create jobs.
Professor Chris Bunce, Research Director at Leukaemia & Lymphoma Research, said he is delighted that the government is showing a continued commitment to life sciences, and improved clinical trials:
“The UK is leading the world in the development of treatments for cancer, however, its inability to rapidly translate scientific findings into early phase clinical trials remains a major hurdle. Clinical trials, particularly for blood cancer, are difficult to set up and it can take anything from four to ten years to complete a trial and analyse the results. TAP is designed to tackle these problems
“We are delighted that the government is committed to improving access to clinical trials. This is particularly important given the squeeze on NHS budgets and increased demand for new treatments. The TAP programme is benefiting patients while using NHS resources more efficiently, and is also attracting investment from the global pharmaceutical industry.
“Our TAP model brings together the NHS, the pharmaceutical industry, and charities, and we are confident that with adequate investment it could be extended to help find new treatments for other diseases.”
To read the report and the TAP case study (page 20) click here.